Skip to main
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed is also well-funded with a solid cash position and has potential for expansion into other areas of the spine market. This makes it a strong and promising company in the medical technology sector. From a third person point of view, Carlsmed's positive outlook can be attributed to its innovative and effective personalized spinal implants, which have resulted in increased adoption and potential for higher reimbursement. The company's AI-based platform and unique features have driven new surgeon adoption and improved gross margins, leading to a favorable market opportunity. However, there are potential risks and competition to consider, but the company's strong cash position, potential for expansion, and expected profitability make it a promising investment in the medical technology sector.

Bears say

Carlsmed is a commercial-stage medical technology company with a differentiated AI-enabled personalized solution for spine surgery. Despite positive physician feedback and a strong market position, their growth potential may be limited due to the specialized nature of their product. This could lead to challenges in achieving profitability and the company's financials may be negatively impacted by slower adoption rates and potential reimbursement issues.

Carlsmed Inc (CARL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.